Bellerophon Therapeutics, Inc.

OTCPK:BLPH Stock Report

Market Cap: US$464.8k

Bellerophon Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Jan 06
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Sep 27

Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17

Aug 15

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Jan 18
Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Bellerophon Therapeutics EPS misses by $0.01

Nov 05

CEO

Craig Jalbert (62 yo)

less than a year

Tenure

Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...